Alteplase use for prevention of central line occlusion in a preterm infant

Annals of Pharmacotherapy

Volumn 36, Issue 2, 2002, Pages 272-274

  Lee, Edith K ^a  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

Author keywords

Alteplase; Neonates; Occluded catheters

Indexed keywords

ALCOHOL; ALTEPLASE; AMPHOTERICIN B; FIBRINOLYTIC AGENT; HYDROCHLORIC ACID; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ANAPHYLAXIS; ARTICLE; BLEEDING; CASE REPORT; CATHETER; DRUG USE; HUMAN; MALE; NEWBORN; PREMATURITY; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR;

EID: 0036161906     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.10384     Document Type: Article

References (10)

1. Activity and dosage of alteplase dilution for clearing occlusions of venous-access devices
2. Alteplase (rt-PA) use in infants and children
3. Alteplase: A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction
4. Bioactivity of cryopreserved alteplase solutions
5. Investigational use of tissue plasminogen activator (t-PA) for occluded central venous catheters
6. Use of tissue plasminogen activator to clear blocked central venous lines in pediatric patients: A prospective cohort study
7. The use of recombinant tissue plasminogen activator (rTPA) in infants and children
8. Use of tissue type plasminogen activator in neonates: Case reports and review of the literature
9. Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA)
10. The use of aliquoted and frozen tPA in central venous line occlusions